$2.00
+0.07 (+3.63%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where KPTI is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
36 interventional · 1 expanded access · 19 with posted results
Held by 7 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, MILLENNIUM MANAGEMENT LLC, MARSHALL WACE, LLP, RENAISSANCE TECHNOLOGIES LLC, Squarepoint Ops LLC, +2 more) · FINRA short interest 2.7 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.NCT04414475Overall Response Rate (ORR)Randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Selinexor, Dexamethasone, Bortezomib | Multiple Myeloma, Refractory | 127 | Jan 2028 | ≤ 529 d | 2026-02-02 |
| A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate ThrombocytopeniaNCT05980806Proportion of Participants with Spleen Volume Reduction ≥35% (SVR35) at Week 24Non-randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Selinexor 60 mg, Selinexor 40 mg, Ruxolitinib, Pacritinib, Momelotinib | Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia | 58 | Jun 2027 | ≤ 314 d | 2026-02-12 |
| Selinexor and Backbone Treatments of Multiple Myeloma PatientsNCT02343042Phase 1 (Dose-escalation): Maximum Tolerated Dose (MTD)Randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: Selinexor, Dexamethasone, Lenalidomide, Pomalidomide, Bortezomib, Daratumumab, Carfilzomib, Ixazomib, Elotuzumab, Clarithromycin, Belantamab Mafodotin, Mezigdomide | Multiple Myeloma | 300 | Apr 2027 | ≤ 253 d | 2026-07-15 |
| Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)NCT02227251Part 1: Overall Response Rate (ORR)Randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Selinexor, Selinexor, Selinexor | Diffuse Large B-cell Lymphoma | 244 | Dec 2026 | ≤ 133 d | 2026-07-02 |
| A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaNCT04442022Phase 2: Overall Response Rate (ORR): Based on Lugano Criteria 2014Randomized · Double-masked · Treatment | Phase 2/3 | Active, not recruiting | Drug: Selinexor (combination therapy), Selinexor (combination therapy), Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy) | Relapsed/Refractory Diffuse Large B-cell Lymphoma | 501 | Dec 2026 | ≤ 133 d | 2026-07-02 |
| A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated MyelofibrosisNCT04562870Percentage of Participants with Spleen Volume Reduction of Greater Than or Equal to (≥) 35 Percent (%) (SVR35)Randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Selinexor · Other: Physician's Choice Treatment | Myelofibrosis | 112 | Sep 2026 | ≤ 41 d | 2026-07-02 |
| Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial CarcinomaNCT05611931Investigator assessed Progression Free Survival (PFS) per RECIST v1.1Randomized · Double-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Selinexor, Matching Placebo for selinexor | Endometrial Cancer | 257 | Aug 2026 | ≤ 11 d | 2026-05-29 |
| Study of Selinexor in Combination With Ruxolitinib in MyelofibrosisNCT04562389Phase 3: Proportion of Participants with Spleen Volume Reduction (SVR) of Greater than or Equal to (>=) 35 Percent (%) (SVR35) at Week 24 Measured by the Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) ScanRandomized · Double-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Selinexor, Selinexor, Ruxolitinib · Other: Placebo | Myelofibrosis | 353 | 2026-02-20actual | — | 2026-04-09 |
| Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)NCT04607772Phase 1: Maximum Tolerated Dose (MTD)Non-randomized · Open-label · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: Sponsor decision | Drug: Selinexor, Rituximab, Bendamustine, Polatuzumab Vedotin, Ibrutinib, Lenalidomide, Tafasitamab, Venetoclax, Gemcitabine, Oxaliplatin | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | 0 | Dec 2025 | — | 2025-10-03 |
| Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer IndicationsNCT02649790Part A1, A2, B, C, D, E, F: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)Non-randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: KPT-8602, ASTX727, Dexamethasone | Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS | 277 | 2024-08-31actual | — | 2025-03-19 |
| Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination TreatmentNCT04256707Monotherapy Period: Area Under the Concentration-Time Curve from Time Zero to Time of Last Concentration (AUC 0-t) of Selinexor in Patients with Normal, Moderate and Severe Hepatic FunctionRandomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: Selinexor 100 mg, Docetaxel, Pembrolizumab, FOLFIRI, Selinexor 40 mg, Selinexor 80 mg, Selinexor 60 mg | Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC), Other Solid Tumors | 126 | 2024-07-31actual | — | 2025-03-19 |
| Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced MelanomaNCT04768881results2024-08-23Overall Response Rate (ORR) Assessed as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: The trial was terminated due to a lack of sufficient anti-melanoma tumor signal for the combination of selinexor + pembrolizumab. | Drug: Selinexor, Pembrolizumab | Locally Advanced Unresectable or Metastatic Melanoma | 15 | 2023-09-22actual | — | 2024-08-23 |
| A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent GlioblastomaNCT04421378results2024-12-16Phase 1a and 1b: Maximum Tolerated Dose of SelinexorRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Upon further consideration of the existing data and the competitive landscape, Karyopharm Therapeutics Inc has decided not to pursue the ongoing development of Selinexor in GBM at this time. | Drug: Selinexor, Temozolomide (TMZ), Lomustine (CCNU), Bevacizumab, Carmustine · Radiation: Standard Fractionated Radiation therapy (RT) · Device: TTField | Glioblastoma Multiforme | 74 | 2023-07-03actual | — | 2024-12-16 |
| A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS MutationsNCT04854434results2023-11-03Arm B and C: Progression-free Survival (PFS) as Assessed by the Investigator Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision | Drug: Selinexor, Pembrolizumab, Trifluridine, Tipiracil | Metastatic Colorectal Cancer | 13 | 2022-06-24actual | — | 2023-11-03 |
| Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]NCT03555422Progression Free Survival (PFS)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Selinexor, Matching placebo for selinexor | Endometrial Cancer | 263 | 2022-01-22actual | — | 2026-04-13 |
| PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)NCT02702492results2024-11-25Maximum Tolerated Dose (MTD) for KPT-9274Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: sponsor decision | Drug: KPT-9274, Niacin ER, Nivolumab | Solid Tumors, NHL | 60 | 2021-01-26actual | — | 2024-11-25 |
| Selinexor in Advanced LiposarcomaNCT02606461results2021-12-07Phase 3 Double Blind: Progression-free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Completed | Drug: Selinexor, Placebo | Dedifferentiated Liposarcoma | 342 | 2020-10-28actual | — | 2023-01-23 |
| Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 InfectionNCT04349098results2021-11-01Percentage of Participants With At-least a 2-Point Improvement in Ordinal ScaleRandomized · Single-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Selinexor · Other: Placebo | Coronavirus Infection | 190 | 2020-10-05actual | — | 2023-01-20 |
| Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19NCT04355676Percentage of Participants with at Least a 2 Point Improvement in the Ordinal ScaleRandomized · Open-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: No participants enrolled | Drug: Selinexor | Coronavirus Infection | 0 | 2020-08-30actual | — | 2023-01-20 |
| Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple MyelomaNCT03110562results2021-07-08SVd/Vd Arm: Progression-free Survival (PFS) as Assessed by Independent Review Committee (IRC)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Selinexor, Bortezomib, Dexamethasone | Multiple Myeloma | 402 | 2020-02-18actual | — | 2024-08-21 |
| Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent GliomasNCT01986348results2021-08-026-Month Progression-Free Survival (PFS) RateRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Study was terminated due to Sponsor decision (all except 1 patient were off-treatment and 2 patients were in survival follow-up) | Drug: Selinexor | Glioblastoma, Glioma | 76 | 2020-01-23actual | — | 2023-01-26 |
| Selinexor Treatment of Refractory MyelomaNCT02336815results2020-08-13Part 2: Percentage of Participants With Overall Response Rate (ORR) Per International MyelomaWorking Group (IMWG) as Assessed by an Independent Review Committee (IRC)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Selinexor, Dexamethasone | Multiple Myeloma | 202 | 2019-07-26actual | — | 2023-01-26 |
| Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma PatientsNCT02389543Determine maximum tolerated dose (MTD)Randomized · Open-label · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: Terminated this trial and added a Lenalidomide arm to KCP-330-017 | Drug: Selinexor, Lenalidomide, Dexamethasone | Multiple Myeloma | 0 | Jan 2018 | — | 2023-01-26 |
| Selinexor (KPT-330) in Older Patients With Relapsed AMLNCT02088541results2020-10-08Overall SurvivalRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Selinexor, Hydroxyurea, Ara-C | Acute Myeloid Leukemia (AML) | 317 | 2018-01-08actual | — | 2023-01-26 |
| Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome PatientsNCT02431351Hematologic improvement (based on the 2006 International Working Group (IWG) response criteria)Open-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Trial never opened. | Drug: Selinexor | Myelodysplastic Syndrome | 0 | Dec 2017 | — | 2023-01-26 |
| Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple MyelomaNCT02628704Progression Free Survival (PFS)Randomized · Triple-masked · Treatment | Phase 2 | Withdrawn | Drug: Selinexor, Placebo (for selinexor), carfilzomib, Dexamethasone | Multiple Myeloma | 0 | Jun 2017 | — | 2023-01-26 |
| Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic MalignanciesNCT02025985results2021-02-02Percentage of Participants With Disease Control Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Selinexor | Ovarian Carcinoma, Endometrial Carcinoma, Cervical Carcinoma | 116 | 2017-01-24actual | — | 2023-01-26 |
| A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With SarcomaNCT01896505results2024-01-08Area Under the Concentration-time Curve From the Time Zero to the Last Non-zero Concentration (AUC0-t) of SelinexorRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: KCP-330 | Sarcoma | 54 | 2016-10-21actual | — | 2024-01-08 |
| Selinexor in Initial or Refractory and/or Relapsed Richter's TransformationNCT02138786results2020-02-11Percentage of Participants With Overall Response (Overall Response Rate)Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Lack of efficacy at time of interim analysis | Drug: selinexor | Richter's Transformation | 27 | 2016-08-31actual | — | 2023-01-26 |
| SHIP (Selinexor in Hormone Insensitive Prostate Cancer)NCT02146833results2021-01-26Percentage of Participants With Overall Clinical Benefit Response (CBR)Randomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Due to enrollment challenges. The termination is not a consequence of any safety concern. | Drug: Selinexor | Prostate Cancer | 20 | 2016-04-01actual | — | 2023-01-26 |
| Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor CancerNCT01607905results2021-04-30Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Selinexor, Acetaminophen | Solid Tumor | 192 | 2016-03-15actual | — | 2023-01-26 |
| Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell LymphomaNCT02314247results2018-08-20Overall Response Rate (ORR)Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Due to enrollment challenges | Drug: Selinexor | Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL) | 16 | Jan 2016actual | — | 2023-01-26 |
| Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell CarcinomasNCT02213133results2020-12-07Percentage of Participants With Disease Control Rate (DCR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Non-randomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Due to enrollment challenges and availability of other options for lung cancer patients. The termination is not a consequence of any safety concern. | Drug: Selinexor (KPT-330) | Squamous Cell Carcinoma | 45 | 2015-12-10actual | — | 2023-01-26 |
| Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological CancerNCT01607892results2021-04-01Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)Open-label · Treatment | Phase 1 | Completed | Drug: KPT-330 | Hematological Malignancies | 286 | 2015-10-13actual | — | 2023-01-26 |
| Trial of Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy AdultsNCT02431364results2021-04-13Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)Randomized · Double-masked · Basic science | Phase 1 | Terminatedsponsor's stated reason: Administrative reason | Drug: Verdinexor · Other: Placebo | Healthy | 33 | 2015-10-01actual | — | 2023-01-20 |
| Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) PatientsNCT02367690Presence of Local Skin Reactions (LSR)Randomized · Single-masked · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: Due to enrollment challenges \& improved SOC during run-in phase; no patients received KPT-330. Withdrawal is not a consequence of any safety concern. | Drug: Selinexor · Other: Standard-of-Care, Vehicle Gel | Diabetic Foot Ulcers | 0 | May 2015actual | — | 2023-01-20 |
| Karyopharm Expanded Access Program for SelinexorNCT07215832expanded access | — | Available | Drug: selinexor | Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL), Sarcoma, Neuroglioblastoma, Peripheral T-cell Lymphoma, Endometrial Cancer, Myelofibrosis, Other | — | — | — | 2026-03-02 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19